Pharmacokinetics of amiloride in renal and hepatic disease

The pharmacokinetics of the antikaliuretic amiloride has been studied in healthy controls and in patients with chronic renal failure or hepatitis. It was 40% bound to protein. In healthy volunteers 49% of an oral dose was recovered unchanged in the urine. The renal clearance of amiloride was about 3...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 1987-01, Vol.33 (5), p.493-498
Main Authors: SPAHN, H, REUTER, K, MUTSCHLER, E, GEROK, W, KNAUF, H
Format: Article
Language:English
Subjects:
Adult
Aged
Amiloride - pharmacokinetics
Biological and medical sciences
Blood Proteins - metabolism
Chromatography, Thin Layer
Female
Half-Life
Hepatitis - metabolism
Humans
Kidney Failure, Chronic - metabolism
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Protein Binding
Urinary system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The pharmacokinetics of the antikaliuretic amiloride has been studied in healthy controls and in patients with chronic renal failure or hepatitis. It was 40% bound to protein. In healthy volunteers 49% of an oral dose was recovered unchanged in the urine. The renal clearance of amiloride was about 3 times the creatinine clearance, which means that it was predominantly excreted via tubular secretion. Renal impairment reduced the clearance of amiloride, causing a prolongation of the t1/2 and drug accumulation in plasma. In hepatitis the t1/2 of amiloride was prolonged and the AUC increased. Urinary recovery (Ae) of amiloride was greater in hepatitis patients than in controls.
ISSN:0031-6970
1432-1041
DOI:10.1007/BF00544242